NOI - DNA Sequencing of Bone Marrow Failure Syndro
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.NATIONAL INSTITUTES OF HEALTH.NATIONAL INSTITUTES OF HEALTH OLAO · Response deadline: Mon, 02 Nov 2026
What the government is buying
The National Institutes of Health (NIH) intends to acquire DNA sequencing services focused on bone marrow failure syndromes through a notice of intent (NOI). Bone marrow failure syndromes are a group of rare disorders—such as aplastic anemia, myelodysplastic syndromes, and inherited conditions like Fanconi anemia—in which the bone marrow cannot produce sufficient blood cells. DNA sequencing in this context typically supports research into genetic drivers, diagnostic biomarkers, or potential therapeutic pathways for these conditions.
This work falls under NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing). While this classification code technically covers the commercial manufacture of diagnostic reagents and test kits, federal contracting often uses it more broadly for specialized biotechnology and laboratory services that support diagnostic development. Potential offerors should review the solicitation carefully to confirm whether the requirement centers on sequencing-as-a-service, data analysis, or physical production of diagnostic materials.
This is a Combined Synopsis/Solicitation, meaning the notice combines a synopsis of the proposed contract with the actual solicitation documents. This format streamlines the process by allowing qualified vendors to submit bids without waiting for a separate solicitation release.
Key facts
| Attribute | Value |
|---|---|
| Agency | Department of Health and Human Services, National Institutes of Health, NIH OLAO |
| Notice type | Combined Synopsis/Solicitation |
| Solicitation number | 75N98027Q00027 |
| NAICS | 325413 |
| Set-aside | None specified |
| Response deadline | November 2, 2026, 9:00 AM ET |
| Place of performance | Not specified in notice metadata |
Who can bid
This procurement has no specified small business set-aside, meaning it is open to all qualified businesses regardless of size. Both small and large businesses, as well as nonprofit research institutions, may compete. However, NIH and other HHS components frequently encourage small business participation, and certain contract mechanisms—such as Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) programs—may apply to sequencing-related R&D contracts even when not formally set aside.
Small businesses with capabilities in next-generation sequencing (NGS), bioinformatics analysis of hematologic malignancies or rare diseases, and compliance with NIH research data sharing policies should evaluate this opportunity. Vendors should verify their SAM.gov registration is active and that any required HHS clearance or certification for handling human genetic data is current.
If your business qualifies as small under NAICS 325413 size standards, monitor whether NIH elects to set this aside after initial responses—or whether subcontracting opportunities emerge with a likely prime contractor.
How to put together a competitive bid
For sequencing services contracts of this type, competitive bids typically distinguish themselves through:
Technical approach specificity: Detail your sequencing platform (Illumina, PacBio, Oxford Nanopore, etc.), coverage depth, quality control metrics, and turnaround times. For bone marrow failure research, clarify experience with low-input DNA or challenging bone marrow-derived samples.
Bioinformatics pipeline: Describe variant calling, annotation, and reporting workflows tailored to myeloid or inherited bone marrow disorders. Reference adherence to ACMG guidelines or other relevant standards.
Regulatory and data handling: Address CLIA compliance (if applicable), NIH Genomic Data Sharing Policy adherence, dbGaP deposition readiness, and security controls for controlled-access human data.
Personnel qualifications: Highlight molecular geneticists, hematopathologists, or bioinformaticians with peer-reviewed publications in bone marrow failure or related conditions.
Past performance: Cite prior NIH, NCI, or NHLBI sequencing contracts, especially those involving rare disease cohorts or cooperative research agreements.
Since no quantity, value, or incumbent information appears in the metadata, see the solicitation for budget parameters, period of performance, and evaluation criteria weighting.
Next steps
Read the full solicitation on SAM.gov using solicitation number 75N98027Q00027 or searching the notice title. This Combined Synopsis/Solicitation contains the definitive statement of work, deliverables, and evaluation factors.
Note the deadline: Responses are due November 2, 2026, at 9:00 AM Eastern Time—a relatively compressed 11-day window from the posting date. Confirm receipt requirements and submission method (likely through SAM.gov or an NIH e-system).
Verify SAM.gov registration immediately; expired registrations invalidate bids.
Contact the contracting officer with any clarification questions early, given the tight timeline.
View the official notice on SAM.gov →